

Selected Publications

171	R Gomeni, FMM Bressolle-Gomeni, TJ Spencer, SV Faraone, L Fang, A Babiskin. Model-Based Approach for Optimizing Study Design and Clinical Drug Performances of Extended-Release Formulations of Methylphenidate for the Treatment of ADHD. Clin Pharmacol Ther. 2017 Mar 29. doi: 10.1002/cpt.684.
170	J.J. Wilkins, P.LS Chan, J. Chard, G. Smith, M.K Smith, M. Beer, A. Dunn, C. Flandorfer, C. Franklin, R. Gomeni, L. Harnisch, R. Kaye, S. Moodie, M. L. Sardu, E. Wang, E. Watson, K. Wolstencroft and SY A.Cheung on behalf of the DDMoRe consortium. Thoughtflow: Standards and Tools for Provenance Capture and Workflow Definition to Support Model-Informed Drug Discovery and Development. CPT Pharmacometrics Syst Pharmacol. Accepted.
169	Attali P, Gomeni R, Wersinger E, Poli S, Venail F. The Effects of SENS-111, A New H4R Antagonist, On Vertigo Induced by Caloric Test in Healthy Volunteers (HV) is Related to Plasma Concentrations. Clin Ther. 2016 Oct 6; 38(10S):e4. doi: 10.1016/j.clinthera.2016.07.024.
168	R. Gomeni, F. Bressolle, M. Fava. Response surface analysis and non-linear optimization algorithm for maximization of clinical drug performance: Application to extended release and long-acting-injectable paliperidone. J Clin Pharmacol. 2016 Oct; 56(10):1296-306.
167	Laffont CM, Gomeni R, Heidbreder C, Jones JP 3rd, Nasser AF. Population pharmacokinetic modelling after repeated administrations of RBP-6000, a new, subcutaneously injectable, long-acting, sustained-release formulation of buprenorphine, for the treatment of opioid use disorder. J Clin Pharmacol. 2016 Jul;56(7):806-15.
166	R. Gomeni, N. Goyal, F. Bressolle, M. Fava. A novel methodology to estimate the treatment effect in presence of highly variable placebo response. Neuropsychopharmacology Journal, 2015 Oct; 40(11):2588-95
165	GD Schmith, R Singh, R Gomeni, O Graff, AG Hamedani, JS Troughton and SM Learned. Use of Longitudinal Dose–Response Modeling to Support the Efficacy and Tolerability of Alitretinoin in Severe Refractory Chronic Hand Eczema (CHE). CPT Pharmacometrics Syst Pharmacol. 2015 Apr; 4(4):255-62.
164	Marostica E, Russu A, Gomeni R, Zamuner S, De Nicolao G. Population modelling of patient responses in antidepressant studies: a stochastic approach. Mathematical Biosciences. 2015 Mar;261:37-47.
163	Marostica E, Russu A, Gomeni R, Zamuner S, De Nicolao G. Continuous-time Markov modelling of flexible-dose depression trials..J Pharmacokinet Pharmacodyn. 2014 Dec;41(6):625-38.
162	Laffont CM, Gomeni R, Zheng B, Heidbreder C, Fudala PJ, Nasser AF. Population pharmacokinetic modeling and simulation to guide dose selection for RBP-7000, a new sustained-release formulation of risperidone. J Clin Pharmacol. 2015 Jan; 55(1):93-103.
161	AF Nasser, C Heidbreder, R Gomeni, PJ Fudala, B Zheng, MK Greenwald. A Population Pharmacokinetic and Pharmacodynamic Modelling Approach to Support the Clinical Development of RBP-6000, a New, Subcutaneously Injectable, Long-Acting, Sustained-Release Formulation of Buprenorphine, for the Treatment of Opioid Dependence..Clin Pharmacokinet. 2014 Sep;53(9):813-24.
160	SD Targum, DJ Burch, M Asgharnejad, T Petersen, R Gomeni, M Fava. Use of Band-Pass Filter Analysis to Evaluate Outcomes in an Antidepressant Trial for Treatment Resistant Patients. Eur Neuropsychopharmacol. 2014, 24(8):1188–1195
159	R. Gomeni and N. Goyal. Adaptive Randomization Study Design in Clinical Trials for Psychiatric Disorders. J Biomet Biostat 2014, 5:187,1-6
158	S. Yang, R. Gomeni, M. Beerahee. Does Short-Term Placebo Response Predict the Long-Term Observation? Meta-Analysis on Forced Expiratory Volume in 1 Second From Asthma Trials. J Clin Pharmacol. 2014 Nov; 54(11):1207-13.
157	C.M. Laffont, R. Gomeni, B. Zheng, C. Heidbreder, P.J. Fudala, A.F. Nasser. Population pharmacokinetics and prediction of dopamine D2 receptor occupancy after multiple doses of RBP-7000, a new sustained-release formulation of risperidone, in schizophrenia patients on stable oral risperidone treatment. Clin Pharmacokinet. 2014 Jun; 53(6):533-43
156	R. Gomeni. Use of predictive models in CNS diseases. Current Opinion in Pharmacology. 2014; 14: 23–29.
155	R. Gomeni R, M. Fava. The Pooled Resource Open-Access ALS Clinical Trials Consortium. Amyotrophic lateral sclerosis disease progression model. Amyotroph Lateral Scler Frontotemporal Degener. 2014 Mar;15(1-2):119-29
154	R. Gomeni, C. Heidbreder, P.J. Fudala, A.F. Nasser. A model-based approach to characterize the population pharmacokinetics and the relationship between the pharmacokinetic and safety profiles of RBP-7000, a new, long-acting, sustained-release formulation of risperidone. J Clin Pharmacol. 2013; 53(10):1010-9.
153	R. A. Comley, C. A. Salinas, M. Slifstein, M. Petrone, C. Marzano, I. Bennacef, P. Shotbolt, J. Van der Aart, M. Neve, L. Iavarone, R. Gomeni, M. Laruelle, F. A. Gray, R. N. Gunn, E. A. Rabiner. Monoamine transporter occupancy of a novel triple reuptake inhibitor in baboon and human using Positron Emission Tomography. J Pharmacol Exp Ther. 2013; 346(2):311-7
152	N. Goyal, R. Gomeni. A latent variable approach in simultaneous modeling of longitudinal and dropout data in schizophrenia trials. Eur Neuropsychopharmacol. 2013; 23(11):1570-1576.

151	E.Ratti, P.Bettica, R.Alexander, G.Archer, D.Carpenter, G.Evoniuk, R.Gomeni, E.Lawson, M.Lopez, H.Millns, E.A.Rabiner, D.Trist, M.Trower, S.Zamuner, R.Krishnan, and M.Fava. Full Central NK1 Receptor Blockade is Required for Efficacy in Depression: Evidence from Orvepitant Clinical Studies. <i>J Psychopharmacol.</i> 2013; 27(5):424-34.
150	E. Marostica, A. Russu, R.Gomeni, S.Zamuner, G.De Nicolao. A PCA approach to population analysis - With application to a Phase II depression trial. <i>J Pharmacokinet Pharmacodyn.</i> 2013; 40(2):213-27
149	N. Goyal and R. Gomeni. Exposure–Response modeling of anti-depressant treatments: the confounding role of placebo effect. <i>J Pharmacokinet Pharmacodyn.</i> 2013; 40(3):389-99.
148	A. Russu, E. Marostica, G. De Nicolao, A.C. Hooker, I. Poggesi, R. Gomeni, S. Zamuner. Joint Modeling of Efficacy, Dropout, and Tolerability in Flexible-Dose Trials: A Case Study in Depression. <i>Clin. Pharmacol. Ther.</i> 2012 May; 91(5):863-71.
147	N. Goyal and R. Gomeni. A Novel Metric to Assess the Clinical Utility of a Drug in Presence of Efficacy and Dropout Information. <i>Clin. Pharmacol. Ther.</i> 2012; 91(2):215-219.
146	S. Zamuner, E.A. Rabiner, S.A. Fernandes, M. Bani, R.N. Gunn, R. Gomeni, E. Ratti, V.J. Cunningham. A pharmacokinetic PET study of NK ₁ receptor occupancy. <i>Eur J Nucl Med Mol Imaging.</i> 2012 Feb; 39(2):226-35
145	R. Gomeni, M. Simeoni, M. Zvartau-Hind, M. Irizarry, M. Gold. Disease System Analysis approach for modelling Alzheimer's disease progression in subjects on stable acetylcholinesterase inhibitors therapy. <i>Alzheimers Dement.</i> 2012 Jan; 8(1):39-50.
144	A. Russu, I.Poggesi, R. Gomeni, G. De Nicolao. Bayesian population modelling of Phase I dose escalation studies: a Gaussian process approach, <i>IEEE Trans Biomed Eng.</i> 2011 Nov; 58(11):3156-64.
143	A. Russu, G. De Nicolao, I. Poggesi, M. Neve, R. Gomeni, Bayesian population approaches to the analysis of dose escalation studies, <i>Comput Methods Programs Biomed.</i> 2012 Aug;107(2):189-201.
142	P. Bettica, G. Nucci, C. Pyke, L. Squassante, S. Zamuner, E. Ratti, R. Gomeni, R. Alexander. Phase I studies on the safety, tolerability, pharmacokinetics and pharmacodynamics of SB-649868, a novel dual orexin receptor antagonist. <i>J Psychopharmacol.</i> 2012 Aug; 26(8):1058-70.
141	R. Gomeni, E. Merlo-Pich. Trial Simulation to estimate Type I error when a population window enrichment strategy is used to improve efficiency of clinical trials in depression. <i>Eur Neuropsychopharmacol.</i> 2012 Jan;22(1):44-52.
140	R. Bizzotto, S. Zamuner, E. Mezzalana, G. De Nicolao, R. Gomeni, A.C. Hooker, M.O. Karlsson. Multinomial Logistic Functions in Markov Chain Models of Sleep Architecture: Internal and External Validation and Covariate Analysis. <i>AAPS J.</i> 2011 Sep; 13(3):445-63.
139	E. Merlo-Pich, R. C. Alexander, M. Fava, R. Gomeni. Response to: Antidepressant Clinical Trial 'Enrichment Strategies' <i>Clin. Pharmacol. Ther.</i> 2011 Apr; 89(4):486-7.
138	G. Santen, E. van Zwet, P. Bettica, R. Gomeni, M. Danhof, O. Della Pasqua. From trial and error to trial simulation III: a framework for interim analysis in efficacy trials with antidepressant drugs. <i>Clin. Pharmacol. Ther.</i> 2011 Apr; 89(4):602-7.
137	E. Merlo-Pich, R. C. Alexander, M. Fava, R. Gomeni. A new population enrichment strategy to improve efficiency of placebo-controlled clinical trial in depression. <i>Clin. Pharmacol. Ther.</i> , 2010 Nov;88(5):634-42.
136	S. Zamuner, V. Di Iorio, J. Nyberg, R. Gunn, V. Cunningham, R. Gomeni, A. Hooker. Adaptive Optimal Design in PET Occupancy Studies, <i>Clin. Pharmacol. Ther.</i> 2010 May; 87(5):563-71.
135	R. Bizzotto, S. Zamuner., G. De Nicolao, M. Karlsson., R. Gomeni. Multinomial logistic estimation of Markov-chain models for modeling sleep architecture in primary insomnia patients. <i>J Pharmacokinet. Pharmacodyn.</i> 2010 Apr; 37(2):137-55
134	E. Merlo-Pich, P. Bettica and R. Gomeni Bayesian Monitoring and Bootstrap Trial Simulation: A New Paradigm to Implement Adaptive Trial Design for Testing Antidepressant Drugs. <i>The Open Psychiatry Journal</i> , 2009, 3, 20-32.
133	Nucci G., Gomeni R., Poggesi I. Model-based approaches to increase efficiency of drug development in schizophrenia: A can't miss opportunity. <i>Expert Opinion on Drug Discovery</i> , Volume 4, Issue 8, August 2009, Pages 837-856
132	R. Gomeni, A. Lavergne, E. Merlo-Pich. Modelling placebo response in depression trials using a longitudinal model with informative dropout. <i>Eur J Pharm Sci.</i> 2009 Jan 31;36(1):4-10.
131	E Merlo-Pich and R Gomeni. Model-based Approach and Signal Detection Theory to Evaluate the Performance of Recruitment Centers in Clinical Trials with Antidepressant Drugs. <i>Clin Pharmacol Ther.</i> 2008 Sep;84(3):378-84.
130	G. Santen, R. Gomeni, M. Danhof, O. Della Pasqua. Sensitivity of the individual items of the Hamilton depression rating scale to response and its consequences for the assessment of efficacy. <i>J Psychiatr Res.</i> 2008 Oct;42(12):1000-9.
129	AM. Catafau, MM. Penengo, G. Nucci, S. Bullich, I. Corripio, E. Parellada, C. García-Ribera, R. Gomeni, E. Merlo-Pich, Pharmacokinetics and time-course of D2 receptor occupancy induced by atypical antipsychotics in stabilized schizophrenic patients. <i>J Psychopharmacol.</i> 2008 Nov;22(8):882-94..
128	R. Gomeni and E. Merlo-Pich. Bayesian modeling and ROC analysis to predict placebo responders using clinical score measured in the initial weeks of treatment in depression trials. <i>Br J Clin Pharmacol.</i> May;63(5):595-613, 2007.
127	Findling RL, Nucci G, Piergies AA, Gomeni R, Bartolic EI, Fong R, Carpenter DJ, Leeder JS, Gaedigk A, Danoff TM. Multiple dose pharmacokinetics of paroxetine in children and adolescents with major depressive disorder or obsessive-compulsive disorder. <i>Neuropsychopharmacology.</i> 31(6):1274-1285, 2006.
126	Payen S, Zhang D, Maisin A, Popon M, Bensman A, Bouissou F, Loirat C, Gomeni R, Bressolle F, Jacqz-Aigrain E. Population pharmacokinetics of mycophenolic acid in kidney transplant pediatric and adolescent patients. <i>Ther Drug Monit.</i> 27(3):378-388, 2005.

125	S. Payen, A. Faye, A. Compagnucci, C. Giaquinto, D. Gibbs, R. Gomeni, F. Bressolle, E. Jacqz-Aigrain. Bayesian parameter estimates of nelfinavir and its active metabolite, hydroxy-tert-butylamide, in infants perinatally infected with human immunodeficiency virus type 1. <i>Antimicrob Agents Chemother.</i> 49(2):525-535, 2005.
124	K. Muir and R. Gomeni. Non-compartmental analysis. In <i>Pharmacokinetics in Drug Development: Clinical Study Design and Analysis. Part2. Chapter 1</i> , Edited by P.L.Bonate and D.R.Howard, AAPS Pres, Arlington, VA, 2004.
123	F. S. Servin, B. Bougeois, R. Gomeni, F. Mentré, R. Farinotti, J.-M. Desmonts. Pharmacokinetics of Propofol Administered by Target controlled Infusion to Alcoholic Patients. <i>Anesthesiology</i> 99:576–85, 2003.
122	A. Gaudard, E.Varlet-Marie, M.Audran, R.Gomeni, F.Bressolle. Pharmacokinetic-pharmacodynamic modelling of recombinant human erythropoietin in athletes - A population approach. <i>Clinical Drug Investigation.</i> 23(3):167-179, 2003.
121	M. Boucaud, F. Pinguet, S. Culine, S. Poujol, C. Astre, R. Gomeni, F. Bressolle. Modeling plasma and saliva topotecan concentration time course using a population approach. <i>Oncol Res.</i> 13(4):211-219, 2003.
120	L. Iavarone and R.Gomeni. An application of nonlinear mixed-effects modeling to pharmacokinetic data exhibiting nonlinear and time-dependent behavior. <i>J Pharm Sci</i> , 92(1):27-34, 2003.
119	V. Teneggi, L. Squassante, L. Iavarone, S. Milleri, A. Bye and R. Gomeni. Correlation and predictive performances of saliva and plasma nicotine concentration on tobacco withdrawal induced craving. <i>British Journal of Clinical Pharmacology</i> , 54, 407–414, 2002.
118	R.Gomeni, Computer assisted drug development (CADD): an emerging technology for risk assessment and decision making during drug development. <i>DrugPlus International.</i> 1:25-27, 2002.
117	A. Gauvin, F. Pinguet, S. Culine, C. Astre, R. Gomeni, F. Bressolle. A limited-sampling strategy to estimate individual pharmacokinetic parameters of vinorelbine in elderly patients with advanced metastatic cancer. <i>Anticancer Drugs</i> ,13(5):473-480, 2002.
116	R. Gomeni, C. D'Angeli, A.Bye. In-Silico evaluation of optimal In-Vivo delivery properties using Convolution-based model and Clinical Trial Simulation. <i>Pharmaceutical Research</i> , 19(1), 99-103, 2002.
115	S. Zamuner, R. Gomeni, A. Bye. Estimate the time varying brain receptor occupancy in PET imaging experiments using non-linear fixed and mixed effect modeling approach. <i>Nuclear Medicine and Biology Journal.</i> 29(1), 35-43, 2002.
114	R. Gomeni, C. Falcoz, C. D'Angeli, A.Bye. In-Silico predictions of drug properties in man using preclinical data and Computer Assisted Drug Development (CADD) approach. <i>Drug Information Journal.</i> 35(4), 1047-1063, 2001.
113	R. Gomeni, M. Bani, C. D'Angeli, M. Corsi, A. Bye. Computer Assisted Drug Development (CADD): an emerging technology for designing First-Time-In-Man and Proof of Concept studies from preclinical experiments. <i>European Journal of Pharmaceutical Sciences.</i> 13(3), 261-270, 2001.
112	R. Gomeni, V. Teneggi, L. Iavarone, L. Squassante, A. Bye. Population PK/PD of craving in an enforced smoking cessation population: Indirect Response and Probabilistic modeling. <i>Pharmaceutical Research.</i> 18(4), 537-543, 2001.
111	Gauvin, F. Pinguet, S. Culine, C. Astre, R. Gomeni, F. Bressolle. Bayesian Estimate of Vinorelbine Pharmacokinetic Parameters in Elderly Patients with Advanced Metastatic Cancer, <i>Clinical Cancer Research.</i> 6(7), 2690-2695, 2000.
110	R. Gomeni. Emerging technologies and business pressure: the driving forces for an information management reengineering strategy, <i>Drug Information Journal.</i> 34(2) 645-655, 2000.
109	F. Bressolle, J.M. Joulia, F. Pinguet, M. Ychou, C. Astre, J. Duffour and R. Gomeni. Circadian rhythm of 5-fluoracil population pharmacokinetics in patients with metastatic colorectal cancer. <i>Cancer Chemotherapy and Pharmacology.</i> 44(4) 295-302, 1999.
108	P. Joubert, F. Bressolle, A.Gouby, P.Y. Douçot, G. Sassi and R. Gomeni. A population approach of the forecasting of amikacin plasma and urinary levels using a prescribed dosage regimen. <i>European Journal of Drug Metabolism and Pharmacokinetics.</i> 24 (1), 39-46, 1999.
107	F. Bressolle and R. Gomeni. Predictive performance of a semi-parametric method to estimate population pharmacokinetic parameters using NONMEM, <i>J. Pharmacokinet. Biopharm.</i> 26(3), 349-361, 1998.
106	C.Guitton, J.M. Kinowski, R. Gomeni, F. Bressolle. A kinetic model for simultaneous fit of Clozapine and Norclozapine concentrations in chronic schizophrenic patients during long term treatment. <i>Clin. Drug Invest.</i> 16(1), 35-43, 1998.
105	G.M. Pacifici, M.C. Quilici, B. Giulianetti, R. Spisni, M. Nervi, L. Giuliani and R. Gomeni, Ritodrine sulphation in the human liver and duodenal mucosa: interindividual variability. <i>Eur J Drug Metab Pharmacokinet</i> , 23(1),67-74 , 1998.
104	F. Bressolle, M. Audran, R. Gareau, T. Pham and R. Gomeni. Comparison of direct and indirect population pharmacodynamic model: Application to recombinant human erythropoietin in athletes. <i>Journal of Pharmacokin. and Biopharmaceutics</i> , 27,(3), 263-275, 1997.
103	F. Bressolle, M. Audran, R. Garreau, R.D. Baynes, C. Guidicelli and R. Gomeni. Population Pharmacodynamics for Monitoring Epoetin in Athletes. <i>Clin. Drug Invest.</i> 14, (3) 233-242, 1997.
102	G.M. Pacifici, B. Giulianetti, M.C. Quilici, R. Spisni, M. Nervi, L. Giuliani and R. Gomeni. Salbutamol sulphation in the human liver and duodenal mucosa: interindividual variability. <i>Xenobiotica</i> 27,(3) 279-286, 1997.
101	M.A. Ferroni, P.C. Giulianotti, A. Pietrabissa, F. Mosca, R. Gomeni and G.M. Pacifici. Captopril methylation in human liver and kidney: Interindividual variability. <i>Xenobiotica.</i> 26,(8) 877-882, 1996.
100	L.Edno, F.Bressolle, R.Gomeni, C.Bologna, J.Sany and B.Combe, Total and free methotrexate pharmacokinetics in rheumatoid arthritis patients, <i>Therapeutic Drug Monitoring</i> , 18, 128-134, 1996.